All eyes will be on the CSL Limited (ASX: CSL) share price later this month when it hands in its full year results.
Ahead of the release, I thought I would look to see what the market is expecting from the biotherapeutics giant.
What is expected from CSL in FY 2021?
The bad news for the CSL share price is that analysts at Goldman Sachs have tipped the company as one that could negatively surprise this month.
Though, this isn’t necessarily to do with the FY 2021 result itself, but rather its outlook commentary.
Goldman explained: “FY21 result set to be challenging but in itself a minor focus. By reaffirming the FY21 earnings target of +3-8% despite delivering a +25% beat at 1H, CSL guidance points to an earnings decline of (47)-(58)% in 2H21. Whilst management has likely applied more than its usual degree of conservatism amidst so much uncertainty, it is also clear that the company was having to take tough decisions on customer allocations.”
What is the main thing to look for?
The reason the CSL share price has been underperforming this year is concerns over plasma collection headwinds. Goldman suspects that this could lead to cost pressures in FY 2022.
It commented: “Earlier in 2021 there had been some optimism that plasma collection volumes may approach near-normal by early-FY22. In reality, it appears that the industry is still some way short of pre-Covid levels (potentially threatening the strong recovery that had been expected during 2H22), and also that the various costs of collection/processing remain highly elevated (most notably donor fees which constitute >25% of COGS and have increased >50% in the last 18 months).”
“As such, we see scope for cautious commentary on FY22, largely predicated around cost, which may manifest in another year of cautious guidance,” it warned.
Is the CSL share price in the buy zone?
In light of the above, CSL thinks investors should keep their powder dry for the time being.
It has put a neutral rating and $305.00 price target on its shares. Based on the current CSL share price of $291.54, this implies potential upside of 4.5% over the next 12 months.
The post FY 2021 results preview: Is the CSL (ASX:CSL) share price in the buy zone? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
More reading
- Here are 3 dipping ASX shares now ready to rally
- 2 excellent ASX 200 healthcare shares named as buys
- Is it a good time now to buy CSL (ASX:CSL) shares?
- ASX 200 Weekly Wrap: ASX grinds to a halt following new all-time high
- Own CSL (ASX:CSL) shares? Here’s what to look for this reporting season
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3jldlBJ
Leave a Reply